Last reviewed · How we verify
WHO TBM treatment — Competitive Intelligence Brief
phase 3
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
WHO TBM treatment (WHO TBM treatment) — ANRS, Emerging Infectious Diseases. WHO TBM treatment is a standardized therapeutic regimen combining antimicrobial agents optimized for tuberculous meningitis, targeting Mycobacterium tuberculosis in the central nervous system.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| WHO TBM treatment TARGET | WHO TBM treatment | ANRS, Emerging Infectious Diseases | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- WHO TBM treatment CI watch — RSS
- WHO TBM treatment CI watch — Atom
- WHO TBM treatment CI watch — JSON
- WHO TBM treatment alone — RSS
Cite this brief
Drug Landscape (2026). WHO TBM treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/who-tbm-treatment. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab